Navigating the outcome maze: a scoping review of outcomes and instruments in clinical trials in genetic neurodevelopmental disorders and intellectual disability.

Therapeutic advances in rare disease Pub Date : 2024-04-25 eCollection Date: 2024-01-01 DOI:10.1177/26330040241245721
Annelieke R Müller, Nadia Y van Silfhout, Bibiche den Hollander, Dick H C Kampman, Lianne Bakkum, Marion M M G Brands, Lotte Haverman, Caroline B Terwee, Carlo Schuengel, Joost Daams, David Hessl, Frits A Wijburg, Erik Boot, Agnies M van Eeghen
{"title":"Navigating the outcome maze: a scoping review of outcomes and instruments in clinical trials in genetic neurodevelopmental disorders and intellectual disability.","authors":"Annelieke R Müller, Nadia Y van Silfhout, Bibiche den Hollander, Dick H C Kampman, Lianne Bakkum, Marion M M G Brands, Lotte Haverman, Caroline B Terwee, Carlo Schuengel, Joost Daams, David Hessl, Frits A Wijburg, Erik Boot, Agnies M van Eeghen","doi":"10.1177/26330040241245721","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Individuals with genetic neurodevelopmental disorders (GNDs) or intellectual disability (ID) are often affected by complex neuropsychiatric comorbidities. Targeted treatments are increasingly available, but due to the heterogeneity of these patient populations, choosing a key outcome and corresponding outcome measurement instrument remains challenging.</p><p><strong>Objectives: </strong>The aim of this scoping review was to describe the research on outcomes and instruments used in clinical trials in GNDs and ID.</p><p><strong>Eligibility criteria: </strong>Clinical trials in individuals with GNDs and ID for any intervention over the past 10 years were included in the review.</p><p><strong>Sources of evidence: </strong>MEDLINE, PsycINFO, and Cochrane CENTRAL were searched. Titles and abstracts were independently screened for eligibility with a subsample of 10% double-screening for interrater reliability. Data from full texts were independently reviewed. Discrepancies were discussed until consensus was reached.</p><p><strong>Charting methods: </strong>Information was recorded on patient populations, interventions, designs, outcomes, measurement instruments, and type of reporter when applicable. Qualitative and descriptive analyses were performed.</p><p><strong>Results: </strong>We included 312 studies reporting 91 different outcomes, with cognitive function most frequently measured (28%). Various outcome measurement instruments (<i>n</i> = 457) were used, with 288 in only a single clinical trial. There were 18 genetic condition-specific instruments and 16 measures were designed ad-hoc for one particular trial. Types of report included proxy-report (39%), self-report (22%), clinician-report (16%), observer-report (6%), self-assisted report (1%), or unknown (16%).</p><p><strong>Conclusion: </strong>This scoping review of current practice reveals a myriad of outcomes and outcome measurement instruments for clinical trials in GNDs and ID. This complicates generalization, evidence synthesis, and evaluation. It underlines the need for consensus on suitability, validity, and relevancy of instruments, ultimately resulting in a core outcome set. A series of steps is proposed to move from the myriad of measures to a more unified approach.</p>","PeriodicalId":75218,"journal":{"name":"Therapeutic advances in rare disease","volume":"5 ","pages":"26330040241245721"},"PeriodicalIF":0.0000,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11047260/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic advances in rare disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/26330040241245721","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Individuals with genetic neurodevelopmental disorders (GNDs) or intellectual disability (ID) are often affected by complex neuropsychiatric comorbidities. Targeted treatments are increasingly available, but due to the heterogeneity of these patient populations, choosing a key outcome and corresponding outcome measurement instrument remains challenging.

Objectives: The aim of this scoping review was to describe the research on outcomes and instruments used in clinical trials in GNDs and ID.

Eligibility criteria: Clinical trials in individuals with GNDs and ID for any intervention over the past 10 years were included in the review.

Sources of evidence: MEDLINE, PsycINFO, and Cochrane CENTRAL were searched. Titles and abstracts were independently screened for eligibility with a subsample of 10% double-screening for interrater reliability. Data from full texts were independently reviewed. Discrepancies were discussed until consensus was reached.

Charting methods: Information was recorded on patient populations, interventions, designs, outcomes, measurement instruments, and type of reporter when applicable. Qualitative and descriptive analyses were performed.

Results: We included 312 studies reporting 91 different outcomes, with cognitive function most frequently measured (28%). Various outcome measurement instruments (n = 457) were used, with 288 in only a single clinical trial. There were 18 genetic condition-specific instruments and 16 measures were designed ad-hoc for one particular trial. Types of report included proxy-report (39%), self-report (22%), clinician-report (16%), observer-report (6%), self-assisted report (1%), or unknown (16%).

Conclusion: This scoping review of current practice reveals a myriad of outcomes and outcome measurement instruments for clinical trials in GNDs and ID. This complicates generalization, evidence synthesis, and evaluation. It underlines the need for consensus on suitability, validity, and relevancy of instruments, ultimately resulting in a core outcome set. A series of steps is proposed to move from the myriad of measures to a more unified approach.

结果迷宫导航:遗传性神经发育障碍和智力障碍临床试验结果和工具的范围界定综述。
背景:遗传性神经发育障碍(GNDs)或智力障碍(ID)患者通常会受到复杂的神经精神并发症的影响。有针对性的治疗方法越来越多,但由于这些患者群体的异质性,选择关键结果和相应的结果测量工具仍具有挑战性:本范围综述旨在描述 GND 和 ID 临床试验中使用的结果和工具的研究情况:审查对象包括过去10年中针对GNDs和ID患者的任何干预措施的临床试验:检索了MEDLINE、PsycINFO和Cochrane CENTRAL。对标题和摘要进行了独立的资格筛选,并对 10% 的子样本进行了双重筛选,以确保相互之间的可靠性。对全文数据进行独立审核。对不一致之处进行讨论,直至达成共识:记录患者人群、干预措施、设计、结果、测量工具和报告人类型(如适用)等信息。进行了定性和描述性分析:我们纳入了 312 项报告 91 种不同结果的研究,其中认知功能的测量最为常见(28%)。使用了各种结果测量工具(n = 457),其中有 288 种仅在一项临床试验中使用。有 18 种针对特定遗传条件的工具,16 种测量方法是为某项特定试验临时设计的。报告类型包括代理报告(39%)、自我报告(22%)、临床医生报告(16%)、观察者报告(6%)、自我协助报告(1%)或未知报告(16%):对当前实践进行的范围审查显示,GND 和 ID 临床试验的结果和结果测量工具多种多样。这使得归纳、证据综合和评估变得更加复杂。它强调需要就工具的适用性、有效性和相关性达成共识,最终形成一套核心结果。我们提出了一系列步骤,以便从纷繁复杂的测量方法转变为更加统一的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.00
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信